<DOC>
	<DOCNO>NCT01920074</DOCNO>
	<brief_summary>RECTIV® ointment contain 0.4 % nitroglycerin ( NTG ) treatment moderate severe pain associate chronic anal fissure approve June 2011 US Food Drug Administration ( FDA ) adult . The purpose study assess safety , pharmacokinetics , exploratory efficacy RECTIV® adolescent</brief_summary>
	<brief_title>Pharmacokinetic , Safety Exploratory Efficacy RECTIV® Adolescents With Chronic Anal Fissure</brief_title>
	<detailed_description>This open-label , multicenter study conduct 10 site United States . A total 13 pediatric male female patient age ≥12 &lt; 17 year enrol . The patient administer dose Rectiv® twice daily characterize safety , pharmacokinetics , exploratory efficacy Nitroglycerin Ointment 0.4 % ( RECTIV® ) 5 day</detailed_description>
	<mesh_term>Fissure Ano</mesh_term>
	<mesh_term>Nitroglycerin</mesh_term>
	<criteria>Key Male female ≥12 &lt; 17 year age At least 1 anal fissure minimum 3 week duration Anal fissure pain experience last 24 hour Screening enrollment Patient ( parent caregiver appropriate ) provide write informed consent Key Current diagnosis hemorrhoid Hypersensitivity , allergy , contraindication nitroglycerin History hypertension and/or cardiovascular disease History current diagnosis inflammatory bowel disease History current diagnosis fistula ( e ) inano anal abscess Fibrotic anal stenosis Previous anal surgery Diagnosis cancer History migraine chronic headache require treatment analgesic Pregnant lactate female patient Weight &lt; 36 kg</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Anal Fissure</keyword>
	<keyword>Nitroglycerin</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>RECTIV®</keyword>
	<keyword>Pediatric Research Equity Act</keyword>
</DOC>